Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine company, today announces that it has filed a prospectus supplement as part of the renewal of its ...

Valneva’s 2024 Universal Registration Document – available in its entirety in French – includes the Company’s 2024 Annual Financial Report, the Company's Annual Management Report, the Board of ...

Saint Herblain (France), March 24, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is ...

Chikungunya cases have spiked substantially in La Réunion since early 2025, with 8,600 cases recorded and almost 3,000 new cases during the week of March 3 to 9, 2025 1. Similar to the 2005-2006 ...

Hello, and thank you for joining us to discuss Valneva’s Full Year 2024 Results ... States and at the end of the year in Canada and France and we recognized initial sales for the financial ...

Valneva will work with local health authorities and wholesalers on the French island territory to distribute the vaccines.

Shares of VALN stock opened at $7.17 on Friday. Valneva has a 1 year low of $3.62 and a 1 year high of $9.50. The firm’s fifty day simple moving average is $6.34 and its 200 day simple moving ...

During the last three months, 6 analysts shared their evaluations of Valneva VALN, revealing diverse outlooks from bullish to bearish. The following table provides a quick overview of their recent ...

CEO Thomas Lingelbach highlighted that Valneva achieved double-digit year-on-year sales growth, with total product sales surpassing €160 million for 2024, in line with guidance. The company ...